Vonaflex

Lidocaine Lotion


Cymbiotics, Inc
Human Otc Drug
NDC 36590-6461
Vonaflex also known as Lidocaine Lotion is a human otc drug labeled by 'Cymbiotics, Inc'. National Drug Code (NDC) number for Vonaflex is 36590-6461. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Vonaflex drug includes Lidocaine - 4 g/100g . The currest status of Vonaflex drug is Active.

Drug Information:

Drug NDC: 36590-6461
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Vonaflex
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lidocaine Lotion
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Cymbiotics, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LIDOCAINE - 4 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:CUTANEOUS
RECTAL
TOPICAL
VAGINAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 25 Aug, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 05 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: M015
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Cymbiotics, Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2599519
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000175682
M0000897
N0000175426
N0000175976
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:98PI200987
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Amide Local Anesthetic [EPC]
Antiarrhythmic [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Local Anesthesia [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Amides [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
36590-6461-150 g in 1 BOTTLE, PUMP (36590-6461-1)25 Jan, 2023N/ANo
36590-6461-275 g in 1 BOTTLE, PUMP (36590-6461-2)25 Jan, 2023N/ANo
36590-6461-3100 g in 1 BOTTLE, PUMP (36590-6461-3)26 Aug, 2022N/ANo
36590-6461-4150 g in 1 BOTTLE, PUMP (36590-6461-4)26 Aug, 2022N/ANo
36590-6461-5200 g in 1 BOTTLE, PUMP (36590-6461-5)25 Jan, 2023N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses for temporary relief of pain & inflammation uses for temporary relief of pain & inflammation

Product Elements:

Vonaflex lidocaine lotion methylparaben edetate disodium propylparaben water sunflower oil carbomer 940 lavender oil polyoxyl 40 hydrogenated castor oil lidocaine lidocaine propylene glycol diethylene glycol monoethyl ether cetyl esters wax cetostearyl alcohol tetrahydrodiferuloylmethane trolamine .alpha.-tocopherol acetate cyclomethicone 5 fragrance lavender rose orc1004596 arnica montana flower water

Indications and Usage:

Uses for temporary relief of pain & inflammation

Warnings:

For external use only. do not use: on wounds, raw surfaces or blistered areas, with a heating pad, or if allergic to product ingredients when using this product: avoid eye contact; do not use excessive amounts; do not exceed recommended dosage unless directed by doctor; do not bandage applied area. stop and ask doctor if: an allergic reaction occurs; condition worsens or does not improve within 7 days. if pregnant or breast-feeding: consult with doctor before use. if swallowed, get medical help or contact a poison control center. precautions concerning children keep out of reach of children.

Dosage and Administration:

Directions use only as directed. adults & children 12 years or older: apply evenly to affected area not more than 3-4 x daily. for children under 12 years, consult with doctor for recommendations. change in heading as requested after review of draft the indications and directions section was renameded to dosage and administration. this was noted as required 34068-7 this change was made on 7/21/2022 as directed. 07/26/22-- as per validation request, changed directions to come under dosage and administration.

Package Label Principal Display Panel:

Package label and principal display panel vonaflex ndc 36590-6451-03 front & back label ndc-3690-6461-03

Further Questions:

Questions and comments www.optimallabortories.com (212) 535-1700


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.